GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ETON · Sep 30, 2025

Eton Pharmaceuticals, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001437749-25-033619General Corporate
Capex intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

1.26% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

53.55% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

117.54% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

75.05% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.gross_margin

34.97% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.operating_margin

-6.07% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

4.95% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

4.86% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History11 statesHistory building
Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/7 normalizedLevel 3Dec 31, 20240/9 normalizedLevel 3Mar 31, 20250/9 normalizedLevel 3Jun 30, 20250/8 normalizedLevel 3Sep 30, 20250/8 normalizedLevel 3Dec 31, 20257/9 normalizedLevel 3Mar 31, 20267/8 normalizedLevel 3Jun 30, 20267/8 normalizedLevel 3
Period transition

What moved in the state?

Capex Intensity Increased
Previous
0.00%
Current
1.26%
Delta
1.26%
Cash Generation Increased
Previous
42.05%
Current
53.55%
Delta
11.50%
Growth Increased
Previous
108.60%
Current
117.54%
Delta
8.95%
Inventory Pressure Decreased
Previous
125.69%
Current
75.05%
Delta
-50.64%
Margin Decreased
Previous
63.00%
Current
34.97%
Delta
-28.02%
Profitability Increased
Previous
-7.79%
Current
-6.07%
Delta
1.72%
R And D Intensity Decreased
Previous
19.61%
Current
4.95%
Delta
-14.66%
Sbc Intensity Decreased
Previous
11.07%
Current
4.86%
Delta
-6.21%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · ETON Fundamental State →Has State · Eton Pharmaceuticals, Inc. →Transitioned To · ETON Fundamental State →Transitioned To · ETON CAPEX_INTENSITY_INCREASED →Transitioned To · ETON CASH_GENERATION_INCREASED →Transitioned To · ETON GROWTH_INCREASED →Transitioned To · ETON INVENTORY_PRESSURE_DECREASED →Transitioned To · ETON MARGIN_DECREASED →Transitioned To · ETON PROFITABILITY_INCREASED →Transitioned To · ETON R_AND_D_INTENSITY_DECREASED →Transitioned To · ETON SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.